| 【Company Research】Innolight (300308 CH) – Investors focusing on 800G transceivers ramp-up after 1H23 results |
| 【Company Research】CTGDF (601888 CH) – 2Q in line with profit alert; subtle recovery ahead |
| 【Company Research】Henlius Biotech (2696 HK) – Profit turnaround in 1H23 |
| 【Company Research】Tigermed (300347 CH) – Healthy growth amid challenging environment |
| 【Company Research】Yongda Automobiles (3669 HK) – New-car GPM may bottom out in 2H23E |
| 【Company Research】AAC Tech (2018 HK) – 1H23 weakness in-line; Maintain HOLD on fair valuation |
| 【Company Research】PA Good Doctor (1833 HK) – Business restructuring closes to the end |
| 【Company Research】CR Gas (1193 HK) – 1H23 results marginally beat; continue to implement “1+2+N” strategy |
| 【Company Research】GAC Group (2238 HK) – Homegrown brands likely to narrow loss in 2H23 |
| 【Company Research】Weibo (WB US) – Expect mild recovery in 3Q23E |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
